sacubitril

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
OBJECTIVES The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
OBJECTIVES The objective of this study was to determine the cost-effectiveness and cost per quality-adjusted life year (QALY… (More)
  • table 1
  • table 2
  • table 3
  • table 5
  • table 4
Is this relevant?
2016
2016
Valsartan/sacubitril (Entresto, Novartis) is a combination of the neprilysin inhibitor sacubitril and the angiotensin receptor… (More)
Is this relevant?
2016
2016
OBJECTIVES This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability. BACKGROUND… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2016
Review
2016
The PARADIGM-HF study, a large outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
Review
2016
Review
2016
Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first in a new class of drugs that combines… (More)
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Sacubitril was recently approved by the Food and Drug Administration for use in combination with valsartan for the treatment of… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2016
2016
BACKGROUND The prevalence of pre-diabetes mellitus and its consequences in patients with heart failure and reduced ejection… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 1
Is this relevant?
2015
2015
Shown are age-based Kaplan–Meier curves for patients in the PARADIGM-HF trial in the sacubitril–valsartan group and the enalapril… (More)
  • figure 1
Is this relevant?
2015
2015
AIMS LCZ696 (angiotensin receptor neprilysin inhibitor) is a novel drug developed for the treatment of heart failure with reduced… (More)
  • table 1
  • figure 1
  • figure 2
  • table 4
  • figure 3
Is this relevant?